Index

N-acetylaspartate (NAA) 710–11, 721
activation likelihood estimation (ALE) 646, 648
Acute Hangover Scale (AHS) 295
ad libitum self-administration of drugs paradigm 320–1
Addiction Research Center Inventory (ARCI) 266
Addiction Severity Index (ASI) 101
addiction Stroop task 494–6
Adjusting Amount Discounting (AADD) 270
adolescence 11
  craving measures 368–9
  withdrawal effects 15
adrenocorticotropic hormone (ACTH; corticotropin) 412, 414
adult craving measures 369
adversity, early 17–18
affective modulation of startle 573–5
aftereffects of withdrawal and
  aftereffects age 11–12
  of first use 9
  self-reporting 15
  age-related trajectories 7
  agreeableness 111–12
Alcohol Cessation Expectancies
  Questionnaire 474
alcohol consumption
  age of first use 9
  balanced placebo designs (BPDs) 467–8
  behavioral measures of craving
    ad lib drinking 442–3
    drinking speed 443
    operant and choice behavior 443–4
  craving measures
    Alcohol Craving Questionnaire (ACQ) 355
    Alcohol Urge Questionnaire (AUQ) 363
    Jellinek Alcohol Craving Questionnaire (JACQ) 356
    Obsessive-Compulsive Drinking Scale (OCDS) 347–54
    Penn Alcohol Craving Scale (PACS) 354–5
    Preoccupation with Alcohol Scale (PAS) 356–7
    Temptation and Restraint Inventory (TRI) 355–6
  expectancy measures 471
  hangover 293–4
  as a marker for risk 295
  assessment 295
  psychological and personality correlates 294
  influence on sexual behavior 524–5
  magnetic resonance spectroscopy (MRS) imaging 713–23
  pharmacokinetics
    dose, speed and administration method 445
    gender issues 444–5
    PPI 572, 573
    priming 441–6
    sexual dysfunction in males 73
  withdrawal syndrome (AWS) 286–7
Alcohol Craving Questionnaire (ACQ) 355
Alcohol Myopia theory 528
Alcohol Purchase Task (APT) 329–30, 333
Alcohol Urge Questionnaire (AUQ) 267, 363
alcohol use disorder (AUD) 295
Alcohol Withdrawal Symptom Checklist (AWSC) 297
Altered State of Consciousness Scale (ASC) 268
amphetamine withdrawal syndrome (AmWS) 288

amphetamines
inhibitory impairment 145
magnetic resonance
spectroscopy (MRI) imaging 723–32
Anagram Persistence Task (APT) 240
Angling Risk Task (ART) 215
anhedonia 18
anterior cingulate cortex (ACC) 31–2, 35
distress tolerance 250
antisaccade tasks 146–7
approach block 502
approach–avoidance task (AAT) 503–4
attention 32–4
behavioral inhibition 145–6
antisaccade tasks 146–7
countermanding tasks 148
cross-sectional comparisons 149
examination of acute drug effects 149–51
laboratory measures 146–8
memory-guided saccade tasks 147–8
relevance to substance abuse 149–51
measures of
Attention Network Task (ANT) 272
Divided Attention Task (DAT) 272
Rapid Information Processing Task (RIT) 272–3
prefrontal cortex (PFC) 31
Attention Network Task (ANT) 272
attentional bias 31
attentional blink 499
attrition bias 90
audio-enhanced computerized self-interview (ACASI) 92, 93
automatic processes 438–9, 490
avoid block 502
balanced–placebo designs (BPD) 461–2, 467–9
future directions 478–9
Balloon Analogue Risk Task (BART) 212–15, 271

### Index

<table>
<thead>
<tr>
<th>Term</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Behavioral Inhibition</td>
<td>361</td>
</tr>
<tr>
<td>System/Behavioral Activation System</td>
<td>114–15</td>
</tr>
<tr>
<td>(BIS/BAS) scales</td>
<td></td>
</tr>
<tr>
<td>Benzodiazepine Craving Questionnaire (BCQ)</td>
<td></td>
</tr>
<tr>
<td>bioimpedance</td>
<td></td>
</tr>
<tr>
<td>pharmacist</td>
<td></td>
</tr>
<tr>
<td>pharmacokinetics of alcohol</td>
<td>445</td>
</tr>
<tr>
<td>blood oxygen level dependent</td>
<td></td>
</tr>
<tr>
<td>(BOLD) response 646</td>
<td></td>
</tr>
<tr>
<td>Biphasic Alcohol Effects Scale (BAES) 267</td>
<td></td>
</tr>
<tr>
<td>blind source separation (BSS)</td>
<td>609</td>
</tr>
<tr>
<td>blood alcohol</td>
<td></td>
</tr>
<tr>
<td>concentration/level (BAC/L) 144, 445</td>
<td></td>
</tr>
<tr>
<td>blood pressure</td>
<td>268</td>
</tr>
<tr>
<td>brain electrical source analysis (BESA) 615</td>
<td></td>
</tr>
<tr>
<td>brain stimulation</td>
<td>42–4</td>
</tr>
<tr>
<td>brainstem auditory evoked response (BAER) 600</td>
<td></td>
</tr>
<tr>
<td>breath alcohol level (BrAC) 466–7</td>
<td></td>
</tr>
<tr>
<td>breath holding (BH) challenge 239, 243, 244</td>
<td></td>
</tr>
<tr>
<td>Brief Questionnaire on Smoking Urges (BQSU) 267, 363</td>
<td></td>
</tr>
<tr>
<td>caffeine expectancy measures</td>
<td>472</td>
</tr>
<tr>
<td>Cambridge Gamble Task 39</td>
<td></td>
</tr>
<tr>
<td>cannabinoids 688–9</td>
<td></td>
</tr>
<tr>
<td>cannabis</td>
<td></td>
</tr>
<tr>
<td>magnetic resonance spectroscopy (MRI) imaging 732–4</td>
<td></td>
</tr>
<tr>
<td>PPI 575</td>
<td></td>
</tr>
<tr>
<td>priming 447</td>
<td></td>
</tr>
<tr>
<td>withdrawal syndrome (CWS) 288</td>
<td></td>
</tr>
</tbody>
</table>
Index

757

carbon ($^{13}$C) MRS 712–13
carbon dioxide (CO$_2$) challenge 239, 243
case-cross-over design 552–3
catechol-O-methyltransferase gene (COMT) polymorphism 650
cerebral blood flow (CBF) 679
regional (rCBF) 680
Certificate of Confidentiality 14
cessation expectancies 464
choline-containing compounds (Cho) 710, 711, 721–2, 728
Cigarette Evaluation Questionnaire (CEQ) 267
Cigarette Purchase Task (CPT) 330–3
cigarette smoking see nicotine; tobacco smoking
Cigarette Withdrawal Scale (CWS) 297
Clinical Institute of Withdrawal Assessment for Alcohol (CIWA-A) scale 296
Clyde Mood Scale 517
Cognitive and Emotional Preoccupation (CEP) 355–6
Cognitive Automaticity model 438
cognitive enhancers 44–5
cognitive-behavioral therapy (CBT) 549–50
cohort effects 12
cold pressor task (CPT) 237–8, 244, 416
Columbia Card Task (CCT) 215–16
community-based samples 11
comorbidities 83–6
analysis 101–3
empirical relevance 86–8
future directions 103–5
measurement 98–101
methodologies
population selection 91–4
research designs 88–91
sampling 94–8
competing neurobehavioral decision systems (CNDS) 27–8, 30–1
compliance 556
recording substance use 556–7
Composite International Diagnostic Interview (CIDI) 298
Computerized Mirror Tracing Persistence Task (MTPT-C) 241
Computerized Paced Auditory Serial Addition Test (PASAT-C) 241–2
conditioned response (CR) 291
congruent trials 497
Conners continuous performance task (CCPT) 31
conscientiousness 112
contingent negative variation (CNV) 622
continuous performance tasks 138
corticocortisol-releasing hormone (CRH) 412, 414
cortisol 412, 414
countermanding tasks 148
craving 298–300, 345–7
additional indices 364
affective indices 365–6
approach/avoidance motivation 368
behavioral economic measures 366–7
behavioral indices 368
cognitive indices 364–5
impulsivity 367–8
psychophysiological indices 366
assessment instruments 347
alcohol craving measures 347–57
Alcohol Craving Questionnaire (ACQ) 355
Alcohol Urge Questionnaire (AUQ) 363
Benzodiazepine Craving Questionnaire (BCQ) 361
Brief Questionnaire on Smoking Urges (QSU) 363
cigarette craving measures 357–8
Cocaine Craving Questionnaire (CCQ) 358–9
Heroin Craving Questionnaire (HCQ) 360
illicit drug craving measures 358–61
Jellinek Alcohol Craving Questionnaire (JACQ) 356
magnitude estimation 363–4
Marijuana Craving Questionnaire (MCQ) 360–1
Minnesota Cocaine Craving Scale (MCCS) 359
multi-item phasic scales 362–3
Obessive-Compulsive Drinking Scale (OCDS) 347–54
Obessive-Compulsive Drug Use Scale (OCDUS) 359–60
Penn Alcohol Craving Scale (PACS) 354–5
phasic craving measures 361–3
Index

craving (Continued)
- Preoccupation with Alcohol Scale (PAS) 356–7
- Questionnaire on Smoking Urges (QSU) 357
- single-item phasic scales 361–2
- Temptation and Restraint Inventory (TRI) 355–6
- Tobacco Craving Questionnaire (TCQ) 357–8
- tonic craving measures 347–61
- Voris Cocaine Craving Scale (VCCS) 359

behavioral measures
- ad lib drinking 442–3
- drinking speed 443
- operant and choice behavior 443–4

special considerations
- adolescence 368–9
- adults 369
- cultural considerations 369–70
- developmental considerations 368–9

state measures 441–2
- crossover point 328
- cross-sectional studies 12

cue reactivity paradigm 381–2, 399–400
- empirical relevance 382–3
- basic phenomenology 383–4
- efficacy of treatment programs 384–5
- tailoring interventions 385–6
- limitations, shortcomings and future directions 394–5
- cue standardization 395
- ecological validity 398–9
- individual difference variables 399
- predictive value 395
- standardized and validated methods 386–7
- cue presentation mode 389–92
- cue presentation order 388–9
- neural-control cue 387–8

reactivity measurement
type 393–4
- substance factors 392–3
- D-cycloserine 44–5

decisional balance 464
- Deese–Roediger–McDermott (DRM) false memory paradigm 477
- delay discounting 165–6
- cause–effect relations
- human studies 172–3, 185
- nonhuman studies 173–85
- steep delay discounting
- and drug abuse from third variable 185–7
- steep delay discounting as cause of drug abuse 172–80
- steep delay discounting as consequence of drug abuse 180–5
- empirical relevance 169–72
- future directions 197–8
- methodology 187
- assessment in humans 187–90
- assessment in nonhumans 190–5
- population sampling 195–7
- predictable anomalies of choice 168–9
- theoretical background 166–8
- delay-of-gratification (DG) tasks 172
- demand curve analysis 324–7
- 2-deoxy-[18F]fluoro-D-glucose positron emission tomography (FDG PET) 679
- devaluation paradigms 437
- developmental paradigms 437
- developmental progression 8–9
- deviance proneness 12–13
- deviance proneness pathway 16–17
- Devil Task 210–11
- diaries, daily 546
- diazepam 518
- Digit Span 273
- Digit Symbol Substitution Test (DSST) 273
- L-dihydroxyphenylalanine (L-DOPA) 211
- Discomfort Intolerance Scale (DIS) 235–6
- disinhibition 439–40
- distress tolerance 233–4
- limitations, shortcomings and future directions 249–51
- methodologies 235
- Anagram Persistence Task (APT) 240
- behavioral assessment 237–44
- Behavioral Indicator of Resiliency to Distress (BIRD) 242–3
- biological challenge tasks 238–40
- Computerized Mirror Tracing Persistence Task (MTPT-C) 241
- Computerized Paced Auditory Serial Addition Test (PASAT-C) 241–2
- Discomfort Intolerance Scale (DIS) 235–6
- Distress Tolerance Scale (DTS) 235
- Frustration–Discomfort Scale (FDS) 236
- Intolerance for Smoking Abstinence Discomfort 247–8
- Maryland Resource for the Behavioral Understanding of Reinforcement from Negative Stimuli (MRBURNS) 248
- Mirror Tracing Persistence Task (MTPT) 240–1
- novel measures 247–8
- physical stress tolerance 237–40
- psychological distress tasks 240–4
relationship between behavioral measures and substance use 243–4
relationship between self-report and substance use 236–7
self-report assessment 235–7
summary and recommendations 244–6
thermal stress tasks 237–8
Willing to Pay-Distress Intolerance (WTP-DI) 247
Distress Tolerance Scale (DTS) 235
Divided Attention Task (DAT) 272
dizocilpine 572
dopamine 681, 683–7
release relationship 685
dopamine transporter (DAT) 679, 685–6
Dot-Probe Task 365
drug challenge studies 259–60
drug craving see craving
Drug Effect Questionnaire (DEQ) 265
drug self-administration paradigms 315–16, 339
ethical issues 336–8
relevance to addiction psychopharmacology 316–18
standardized and validated paradigms 320–36
self-administration paradigms 320–36
setting and durations 318–19
early adversity 17–18
ecological momentary assessment (EMA) 395, 398, 411, 541–2, 558–9
analytical recommendations 552
case-cross-over design 552–3
individual differences 554
outcome analysis 554–5
time-to-event analyses 553
trajectory of antecedents analysis 553–4
content
cognitive and personality measures 547–8
electronic sensors 548
self-reported survey assessment 547
empirical relevance 543–4
future directions 557
unobtrusive assessment 557–8
intervention 548–50
limitations 555
compliance 556–7
cooperation of users 555
reactivity 556
reporting while intoxicated 555–6
methodological recommendations 550
considerations 552
data acquisition 551
device ergonomics 550
dynamic timing protocol 551
software 550–1
principles 542–3
ecologic validity 543
momentary assessment 542
recurrent assessment 542–3
sampling design 544
event-based assessment 544
time-based assessment 544–6
Ecology of Human Development Theory 19
effects of drugs on humans 259–60, 274
behavioral measures 269
Adjustment Amount Delay Discounting (AADD) 270
Attention Network Task (ANT) 272
Balloon Analogue Risk Task (BART) 271
commercially available packages 273–4
Digit Span 273
Digit Symbol Substitution Test (DSST) 273
Divided Attention Task (DAT) 272
Experiential Discounting Task (EDT) 270
Go/No-Go Tasks 271
GoStop Impulsivity Paradigm 272
Hopkins Verbal Memory Test 273
impulsive action 271–2
impulsive choice 269–71
Monetary Choice Questionnaire 270
nonspecific performance 273
Rapid Information Processing Task (RIT) 272–3
Repeated Acquisition Task (RA) 273
Stop Task 271
time perception 272
Two Choice Impulsivity Paradigm (TCIP) 271
dependent measures 265
Addiction Research Center Inventory (ARCI) 266
Alcohol Urge Questionnaire (AUQ) 267
Altered State of Consciousness Scale (ASC) 268
Biphasic Alcohol Effects Scale (BAES) 267
Brief Questionnaire on Smoking Urges (BQSU) 267
Cigarette Evaluation Questionnaire (CEQ) 267
Drug Effect Questionnaire (DEQ) 265
End of Session Questionnaire (ESQ) 266
Hallucinogen Rating Scale (HRS) 268
Hughes–Hatsukami Nicotine Withdrawal Scale (HHNWS) 267
Opiate Checklist 268
physiological effects 268
Positive and Negative Affect Schedule (PANAS) 266
Profiles of Moods States (POMS) 266
psychophysiological measures 269
self-reported subjective effects 265–8
Smoking Questionnaire 267
effects of drugs on humans
(Continued)
Subjective High
Assessment Scale 267
Visual Analog Scale (VAS) 265–6
methodological considerations
administration route 264
contextual factors 264
dose 264
ethical considerations 263–4
participant instruction 262–3
participant screening 262
participant selection 261
elastic demand 325
electric shocks as stressors 416
electroencephalography (EEG) 599, 630
empirical relevance 600
neurophysiological bases 600–5
relevance to drug dependence 605
situational and trait moderation 605
practical considerations
analysis 610–12
artifact attenuation 609–10
automatic deviance detection 621
automatic stimulus gating 620
channel interpolation 610
controlled/selective attenuation 621–2
electrode location and placement 606
electrodes and electrolytes 606–7
epoching 608
event-related oscillations (EROs) 613–14
event-related potentials (ERPs) 612–13
maximizing data quality 607–8
reference choice 608
sampling rate, filtering and electrode number 607
scalp tomography 614–15
stimulus filtering 620–1
stimulus salience indices 623
sustained attenuation 622–3
spontaneous EEG (S-EEG) 616
dose, time, and baseline dependencies 619
recommendations 619
resting power-spectral drug profiles 616–17
situation-dependent power-spectral drug profiles 618
trait-dependent power-spectral drug profiles 617–18
standardized and validated methods 615–16
acute drug effects 616–19
assessment of distal determinants 627–9
drug abstinence effects and aftereffects 626–7
fundamentals 605–15
measurement paradigms 619–26
theoretical background
event-related potentials (ERPs) and event-related oscillations (EROs) 602–5
frequency domain 600–2
electrooculographic (EOG) artifacts 609
emotion and activation self-regulation (EASR) 39–40
End of Session Questionnaire (ESQ) 266
enhanced reinforcement pathway 16–17
error-related negativity (ERN) 628
escalation 178–9
ethnicity 65
etiology of substance use 8–9
event-based sampling schemes 544
event-related oscillations (EROs) 602–5, 613–14
emotional stimuli and drug cues 625
event-related potentials (ERPs) 602–5, 612–13
executive function 27–8, 45–6
functions and dysfunction 31
attention 32–4
cognitive (behavioral) flexibility 36–7
emotion and activation self-regulation (EASR) 39–40
inhibitory control 34–5
metacognitive processes (MPs) 40–1
planning 38–9
valuing future events 35–6
working memory 37–8
novel conceptual and empirical findings 41–2
brain stimulation 42–4
cognitive enhancers 44–5
real-time fMRI 44
training 42
theoretical status 28
addiction 30–1
comprehensive accounts 29
one cognitive faculty accounts 28–9
synthesis-based approach 31
Expectancies Accessibility Task 476
Experiential Discounting Task (EDT) 270
explicit outcome expectancies 462–5
measures 471
abstinence expectances 474–5
alcohol expectances 471
caffeine expectances 472
other drug expectances 472–4
tobacco use expectances 472
methodological considerations 469–70
specificity of items and scales 470–1
extraversion 111
Extrinsic Affective Simon Task (EAST) 476
eyeblink EMG 571, 580–1
eyeblink response in startle 300, 571
Eysenck Personality Questionnaire (EPQ; EPQ-Revised; EPQ-R) 115–16
Index

face evaluation 522
Facial Action Coding System (EACS) 365
facial electromyography (EMG) 365
false memory paradigm 477
fast Fourier transform (FFT) 610–11
Five Factor Model (FFM) of personality 111–14
Frustration–Discomfort Scale (FDS) 236
Functional and Dysfunctional Impulsivity Scales (F/D-IS) 121
functional magnetic resonance imaging (fMRI) 643–4
see also magnetic resonance spectroscopy (MRI) imaging applications behavioral inhibition paradigms 647–8
cognitive paradigms 644–5
conceptual basis 644
cue reactivity paradigms 645–6
imaging genetics 650
neuroeconomic paradigms 648–50
BOLD-fMRI 651, 653–5
challenges 664–6
data acquisition 656–7
future directions 666–7
challenges 664–6
future directions 666–7
methods 650–1
advantages and disadvantages 651–3
brain response quantification 656–61
experimental design 653–5
innovations 661–4
real-time 44
gamma-aminobutyric acid (GABA) 681
resonance 711–12
gateway drugs 9
gender issues alcohol pharmacokinetics 444–5
roles 66
General Linear Models (GLMs) 656–8
genome-wide association studies (GWAS) 88

[Continued on next page]
impulsivity 135–6
impulsivity-related traits
focal measures 119–20
Barratt Impulsiveness Scale-11 (BIS-11) 120–1
Functional and Dysfunctional Impulsivity Scales (F/D-IS) 121
Impulsiveness–Venturesomeness–Empathy Questionnaire (I-7) 121–2
multiple trait model of impulsivity (UPPS-P) 122–4
Sensation Seeking Scale-Form V (SSS-V) 121
Incentive Sensitization theory 293
incongruent trials 497
independent components analysis (ICA) rejection 609, 610
inelastic demand 178–9, 324
inhibition 136
inhibitory control 34–5
interbeat intervals (IBIs) 581–2
International Personality Item Pool (IPIP) 118
inter-trial interval (ITI) 191
Intolerance for Smoking Abstinence Discomfort 247–8
Iowa Gambling Task (IGT) 39, 220–3, 644–5
Item Response Theory (IRT) 16, 20
Jellinek Alcohol Craving Questionnaire (JACQ) 356
late positive component (LPC) 623, 624–5
learning theory 436–7
Letter n-Back Test 37
Lewis (LEW) strain rats 176, 186
life stress 17–18
local autoregressive average (LAURA) 615
long-term depression (LTD) 683
loudness-dependent auditory ERP (LDAERP) 620–1
low-impulsive (LoI) choices 173–80, 196
low-resolution brain electromagnetic tomography (LORETA) 615, 623
MacAndrew Scale (MAC) 294
magnetic resonance spectroscopy (MRI) imaging 709
see also functional magnetic resonance imaging (fMRI)
limitations and future applications 738–42
methodological aspects carbon ($^{13}$C) MRS 712–13
phosphorus ($^{31}$P) MRS 712
proton ($^{1}$H) MRS 710–12
methodologies alcohol 713–23
amphetamine 723–32
methamphetamine (MA) 723–9
3,4-methylenedioxy-methamphetamine (MDMA) 729–32
$[^{18}$F]-N-methylspiperone PET (NMSP PET) 679
MIMIC models 15
Minnesota Multiphasic Personality Inventory (MMPI) 294
Minnesota Cocaine Craving Scale (MCCS) 359
Mirror Tracing Persistence Task (MTPPT) 240–1
mismatch negativity (MMN) 621
Monetary Choice Questionnaire 270
Montreal Imaging Stress Test (MIST) 425
Multidimensional Personality Questionnaire (MPQ) 116
multilevel modeling (MLM) 521
multilevel probabilistic models 16–20
Multiple Choice Procedure (MCP) 328–9, 333–4
N400 paradigms 621
naltrexone 384
negative difference (Nd) wave 621
negative reinforcement 290–3
NEO-Five Factor Inventory (NEO-FFI) 117
neural-control cue 387–8
neuroticism 111
neurotransmitters, effect of chronic drug use excitatory neurotransmitters 682
cannabinoids 688–9
dopamine 683–7
glutamate 682–3
memory: measures of 273
Digit Span 273
Hopkins Verbal Memory Test 273
Repeated Acquisition Task (RA) 273
memory-guided saccade tasks 147–8
metacognitive processes (MPs) 40–1
methamphetamine (MA) 723–9
3,4-methylenedioxy-methamphetamine (MDMA) 729–32
$[^{18}$F]-N-methylspiperone PET (NMSP PET) 679
MIMIC models 15
Minnesota Multiphasic Personality Inventory (MMPI) 294
Minnesota Cocaine Craving Scale (MCCS) 359
Mirror Tracing Persistence Task (MTPPT) 240–1
mismatch negativity (MMN) 621
Monetary Choice Questionnaire 270
Montreal Imaging Stress Test (MIST) 425
Multidimensional Personality Questionnaire (MPQ) 116
multilevel modeling (MLM) 521
multilevel probabilistic models 16–20
Multiple Choice Procedure (MCP) 328–9, 333–4
N400 paradigms 621
naltrexone 384
negative difference (Nd) wave 621
negative reinforcement 290–3
NEO-Five Factor Inventory (NEO-FFI) 117
neural-control cue 387–8
neuroticism 111
neurotransmitters, effect of chronic drug use excitatory neurotransmitters 682
cannabinoids 688–9
dopamine 683–7
glutamate 682–3
memory: measures of 273
Digit Span 273
Hopkins Verbal Memory Test 273
Repeated Acquisition Task (RA) 273
memory-guided saccade tasks 147–8
metacognitive processes (MPs) 40–1
methamphetamine (MA) 723–9
3,4-methylenedioxy-methamphetamine (MDMA) 729–32
$[^{18}$F]-N-methylspiperone PET (NMSP PET) 679
MIMIC models 15
Minnesota Multiphasic Personality Inventory (MMPI) 294
Minnesota Cocaine Craving Scale (MCCS) 359
Mirror Tracing Persistence Task (MTPPT) 240–1
mismatch negativity (MMN) 621
Monetary Choice Questionnaire 270
Montreal Imaging Stress Test (MIST) 425
Multidimensional Personality Questionnaire (MPQ) 116
multilevel modeling (MLM) 521
multilevel probabilistic models 16–20
Multiple Choice Procedure (MCP) 328–9, 333–4
N400 paradigms 621
naltrexone 384
negative difference (Nd) wave 621
negative reinforcement 290–3
NEO-Five Factor Inventory (NEO-FFI) 117
neural-control cue 387–8
neuroticism 111
neurotransmitters, effect of chronic drug use excitatory neurotransmitters 682
cannabinoids 688–9
dopamine 683–7
glutamate 682–3
Index

nicotine 689
opioids, endogenous 687–8
serotonin 687
inhibitory neurotransmitters 681–2
overview 681
nicotine craving measures
Brief Questionnaire on Smoking Urges (QSU) 363
Questionnaire on Smoking Urges (QSU) 357
Tobacco Craving Questionnaire (TCQ) 357–8
dependence 1
effect on excitatory neurotransmitters 689
PPI 572–3
priming 446–7
withdrawal syndrome (NWS) 287–8, 289–90
Nicotine and Other Substances Interaction Expectancies Questionnaire (NOSIE) 474–5
Nicotine Dependence Syndrome Scale (NDSS) 298
Obsessive-Compulsive Drinking Scale (OCDS) 347–54
Obsessive-Compulsive Drug Use Scale (OCD-US) 359–60
odds ratio (OR) 84, 101
omitted variable bias 89, 91
openness 112
operant learning theory 321–8
Opiate Checklist 268
opiate withdrawal syndrome (OWS) 289
opioids
endogenous 687–8
magnetic resonance spectroscopy (MRS) imaging 738
outcome analyses 554–5
outcome expectancies 460
Paced Auditory Serial Addition Test (PASAT) 420
parental effects in smoking patterns 10
Pavlovian-to-Instrumental Transfer (PIT) effect 437
Penn Alcohol Craving Scale (PACS) 354–5
period effects 12
personality assessment 111–12
empirical relevance 112–14
focal measures of impulsivity-related traits 119–20
Barratt Impulsiveness Scale-11 (BIS-11) 120–1
Functional and Dysfunctional Impulsivity Scales (F/D-IS) 121
Impulsiveness–Venturesomeness–Empathy Questionnaire (I-7) 121–2
multiple trait model of impulsivity (UPPS-P) 122–4
Sensation Seeking Scale-Form V (SSS-V) 121
limitations, shortcomings and future directions 124–6
methodologies 114
Behavioral Inhibition System/Behavioral Activation System (BIS/BAS) scales 114–15
Big Five Inventory (BFI) 117–18
Eysenck Personality Questionnaire (EPQ; EPQ-Revised; EPQ-R) 115–16
five-factor measures 117–18
International Personality Item Pool (IPIP) 118
Multidimensionality Personality Questionnaire (MPQ) 116
NEO-Five Factor Inventory (NEO-FFI) 117
Revised NEO Personality Inventory (NEO PI-R) 117
Schedule of Nonadaptive and Adaptive Personality (SNAP) 116
Sensitivity to Punishment and Sensitivity to Reward Questionnaire (SPSRQ) 115
seven-factor measures (HEXACO-PI-R) 119
six-factor measures (HEXACO-PI-R) 118–19
Temperament and Character Inventory (TCI) 119
three-factor measures 115–16
two-factor measures 114–15
Zuckermann–Kuhlman Personality Questionnaire (ZKP-III-R) 118
phasic craving 346
phencyclidine 572
PhenX project 20
phosphomonoesters (PME) 712
phosphorus ($^{31}$P) MRS 712
photoplethysmograph 581
physiological effects of drugs 268
placebo designs 460–1
placebo designs, balanced (BPD) 461–2, 467–9
placebo-controlled designs 466–9
planning 38–9
Point Subtraction Aggression Paradigm 527
positive allosteric modulators (PAMs) 683
Positive and Negative Affect Schedule (PANAS) 266
positive reinforcement 291
positron emission tomography (PET) imaging 677–8
analytic methods
model development 695–6
partial volume error correction 696
brain studies
blood flow 695
glucose metabolism 691–5
effects of chronic drug use on neurotransmitters
positron emission tomography (PET) imaging
(Continued)
excitatory neurotransmitters 682–9
inhibitory neurotransmitters 681–2
overview 681
empirical relevance 680–1
future in substance abuse studies 698–700
history in drug abuse research 679–80
limitations, challenges and future directions 696–8
measuring substance abuse effects 691
role learning in addiction 690–1
study types 691
substance abuse susceptibility 689–90
preference reversals 168
prefrontal cortex (PFC) 29
attention 31
distress tolerance 250
stimulation 42–4
Preoccupation with Alcohol Scale (PAS) 356–7
prepulse inhibition (PPI) 300, 572
developmental factors 585
studies 579
primary comorbidities 98
Prisoner’s Dilemma 529
probabilistic models, multilevel 16–20
Profile of Mood States (POMS) 101, 266
propensity scores 18
prosaccade tasks 146
proton (1H) MRS 710–12
psychometrics
task reliability 151–2
task validity 152
clinical versus control comparisons 152–3
interrelationships among tasks 154–5
performance and trait impulsivity 153–4
psychophysiology
empirical relevance 569–70
heart rate 575–7
skin conductance 577–8
startle reflex 570–5
limitations, shortcomings and future directions 583–4
developmental factors 585–6
individual difference variables 584–5
predictive validity 586
standardized and validated methods
general considerations 578–9
procedural considerations 579–83
Questionnaire on Smoking Urges (QSU) 357
race issues 63–4
definition of race 64–5
limitations and future directions 75–6
measuring race 69
recommendations 69–71
substance abuse prevalence rates by race 66–7
risk factors for USA 67–9
radiant heat stimulation 238
randomized-quit-time (RQT) 627
Rapid Information Processing Task (RIT) 272–3
Rapid Visual Information Processing (RVIP) 622
Raven Progressive Matrices 42
reactivity 556
Reading the Mind in the Eyes Task (RMET) 523
regions of interest (ROIs) 653, 656–8
renewal effect 398
Repeated Acquisition Task (RA) 273
response cost 367
Revised NEO Personality Inventory (NEO PI-R) 117
reward seeking, age effects 11
rewarding stimuli 436
rimonabant 688–9
risk taking 209–10, 226
behavioral tasks
Angling Risk Task (ART) 215
Balloon Analogue Risk Task (BART) 212–15
Columbia Card Task (CCT) 215–16
Iowa Gambling Task (IGT) 220–3
non-appetitive process tasks 224–5
performance as proxy for risky behavior 226
Rogers Decision Making Task (RDMT) 223–4
Slovic’s Devil Task 210–11
Wheel of Fortune (WOF) 216–20
Rogers Decision Making Task (RDMT) 223–4
saccades
antisaccade tasks 146–7
memory-guided saccade tasks 147–8
sampling methodological issues 10–11
scrap tomography 614–15
Schedule of Nonadaptive and Adaptive Personality (SNAP) 116
school-based samples 10–11
science of addiction psychopharmacology 1–3
secondary comorbidities 98
self-administration of drugs paradigms
estimation measures 328–34
implicit self-administration paradigms 334–6
methods from operant learning theory and behavioral economics 321–8
unrestricted (ad libitum) consumption 320–1
self-report distress tolerance 244, 245
self-reporting 13
validation 13–14
Semi-Structured Assessment for the Genetics of Alcohol (SSAGA) 362
Sensation Seeking Scale-Form V (SSS-V) 121
Sensitivity to Punishment and Sensitivity to Reward Questionnaire (SPSRQ) 115
serotonin 681, 687
Index

sex of sufferer 63–4
definition of sex 66
limitations and future directions 75–6
measuring sex 74–5
recommendations 75
substance abuse prevalence rates by sex 71–2
risk factors for USA 72–4
sexual behavior, influence of alcohol 524–5
sexual dysfunction in males from alcohol abuse 73
single nucleotide polymorphisms (SNPs) 88
single photon emission computed tomography (SPECT) 671, 679, 684
Situation by Trait Adaptive Response (STAR) model 624
six-factor personality measure (HEXACO-PI-R) 118–19
skin conductance 577–8
procedural considerations 582–3
skin conductance level (SCL) 583
skin conductance response (SCR) 300
Slovic’s Devil Task 210–11
smaller-sooner (SS) versus larger-later (LL) choices 166–8
delay discounting 168–9
study methodology 187
choosing between dependent measures 190
hypothetical health gains and costs 188
hypothetical monetary gains and costs 187–8
nonhuman subjects 190–5
non-systematic data 190
potentially real monetary gains and costs 188–9
real non-monetary gains 189–90
Smoking Abstinence Questionnaire 474
Smoking Questionnaire 267
smoking see nicotine; tobacco smoking
social cognition 40
social context experimental methods 515–16, 533
acute drug effects on social interaction 521–2
aggressive behavior 527–8
choice of interaction 525
cooperation and pro-social behavior 529
emotion perception 523–4
hypothetical social behavior 524–5
impression formation 522
methodological considerations 530
other social behaviors 530
social behavior components 522–4
structured social behavior 525–30
summary 531
unstructured/semi-structured tasks 530–1
verbal behavior 525–7
bidirectional interactions 532
study designs 532–3
influence of social setting 516
methodological considerations and future directions 519–21
social interaction manipulation designs 518–19
social stressor designs 519
social versus isolated setting designs 516–18
social transitions 12
sphygmomanometers 581
spontaneous processes 490
startle reflex 569, 570–5
procedural considerations 579–81
startle response 300–1
Stimulant Effect Expectancy Questionnaire 474
stimulus onset asynchrony (SOA) 497–8
stimulus–outcome–response (S–O–R learning) 491
stimulus-preceding negativity (SPN) 622, 625
Stimulus–Response Compatibility (SRC) Task 439, 501–2
stop signal reaction time task (SSRT) 34
stop-signal tasks 139–41
Stop Task 271
stress and affective inductions 411–12
application to addiction research 412–13
limitations, shortcomings and future directions 425–7
neuroimaging studies 422–5
pharmacologic stressors 413
adrenergic agents 415
HPA axis peptides 413–14
serotonergic agents 414–15
summary 415–16
physical stressors 416
auditory stressors 417
summary 418
tactile stressors 416–17
visual stressors 417–18
psychological stressors 418
guided imagery 418–19
mental arithmetic tasks 420–1
social interaction tasks 420
speech tasks 419
summary 422
trier social stress test (TSST) 421–2
stress imagery test 520
stress–negative affect pathway 16–17
Stroop color–word task 35
Subjective High Assessment Scale 267
substance expectancies 479
empirical evidence
balanced-placebo designs (BPD) 461–2
explicit outcome expectations 462–5
implicit outcome expectations 465–6
placebo designs 460–1
stimulus expectancies 460–2
future directions 478–9
limitations 477–8
standardized and validated methods
assessing explicit expectancies 469–75
assessing implicit expectancies 475–7
balanced-placebo designs (BPD) 467–9
other design considerations 469
Index

substance expectancies (Continued)
placebo efficacy 466–7
placebo-controlled designs 466–9
theoretical background and definitions 459–60
substance priming 435–6, 451–3
limitations, shortcomings and future directions 448
dose and priming thresholds 449
multidisciplinary research 451
procedures and measures 450–1
time issues 449–50
methodology and current practices 440
cross priming 447
dependent variables 441–4
experimental design 440–1
genetics 447
pharmacokinetics of alcohol 444–6
physiological measures 444
priming with other substances 446–7
treatment 448
theoretical models and empirical evidence 436
automatic processes and biases 438–9
disinhibition 439–40
learning theory 436–7
subjective responses 437–8
sustained attention 31
synapses 681
taste test 442–3
Taste-Rating Task (TRT) 334–6
Taylor Aggression Paradigm 527
Temperament and Character Inventory (TCI) 119
temperature, body 268
Temptation and Restraint Inventory (TRI) 385–6
thermal stress tasks 237–8
third variables 18–19
Time Line Follow-Back 13–14
time perception 272

Time Reference Inventory 165
time-based sampling schemes 544–6
time-to-event analyses 553
Tobacco Craving Questionnaire (TCQ) 357–8
tobacco smoking see also nicotine
age of first use 9
expectancy measures 472
mortality 1
tolerance to substances 15
tonic craving 346
Tower of Hanoi Task 38
Tower of London 38
training for executive function 42
trait impulsivity task performance 153–4
transcranial direct current stimulation (tDCS) 39, 43–4
transcranial magnetic stimulation (TMS) 36, 37, 43
Trier Social Stress Test (TSST) 421–2, 519
tryptophan depletion (TD) 414–15
Two Choice Impulsivity Paradigm (TCIP) 271
ultrasonic vocalizations (USV) 300
unconditioned response (UCR) 291
unconditioned stimulus (UCS) 291
unemployment and poverty 68
unrestricted self-administration of drugs paradigm 320–1
UPPS Impulsive Behavior Scale (UPPS) 123–4, 153
UPPS-P Impulsive Traits Assessment 122–4
USA, risk factors for substance abuse
race 67–9
sex 72–4
valuing future events 35–6
Visual Analog Scale (VAS) 265–6
visual probe task 496–7

Voris Cocaine Craving Scale (VCCS) 359
voxel-wise analyses 657
Wheel of Fortune (WOF) 216–20
Willing to Pay-Distress Intolerance (WTP-DI) 247
Wisconsin Card Sorting Task (WCST) 37
withdrawal and aftereffects 281–2
adolescents 15
behavioral economic approach 301–2
definition of withdrawal 283–5
drug-precipitated withdrawal 289–90
substance dependence context 285–6
withdrawal syndrome examples 286–9
drug craving 298–300
hangover 293–4
as a marker for risk 295
assessment 295
other drugs 294
psychological and personality correlates 294
measurement 295–8
negative reinforcement 290–3
psychophysiological assessment 300–1
recommendations 302–3
symptoms 284
withdrawal syndromes
alcohol (AWS) 286–7
cannabis (CWS) 288
nicotine (NWS) 287–8, 289–90
other drugs 288–9
word association 475
working memory (WM) 37–8, 622
yohimbe 415

Zimbardo Time Perspective Inventory (ZTPI) 165–6
Zuckermann–Kuhlman Personality Questionnaire (ZKP-III-R) 118